Damora Therapeutics is trading 5.4% down at $23.21, with no confirmed catalyst identified.
- No company-specific announcement dated September 17, 2026, was identified; the latest investor-relations release was a September 3 inducement-grants announcement.
- The S&P 500, Nasdaq Composite, and Dow Jones are all higher, creating a divergence from the stock’s decline.
- The reason remains unclear and should be rechecked for delayed news.